omniture
logo
Search
腾盛博药
Media Room

Latest News

rss

Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease

DURHAM, N.C. and BEIJING, Oct. 9, 2021 /PRNewswire/ -- Brii Biosciences

2021-10-09 03:07 5134

Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021

DURHAM, N.C.and BEIJING, Oct. 4, 2021 /PRNewswire/ -- Brii Biosciences

2021-10-04 08:00 3101

Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy

DURHAM, N.C. and BEIJING, Sept. 28, 2021 /PRNewswire/ -- Brii Biosciences

2021-09-28 08:00 2829

Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients

DURHAM, N.C. and BEIJING, Sept. 7, 2021 /PRNewswire/ -- Brii Biosciences

2021-09-07 19:04 3965

Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients

DURHAM, N.C. and BEIJING, Aug. 25, 2021 /PRNewswire/ -- Brii Biosciences

2021-08-25 08:42 2252

Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19

846 outpatients at high risk of clinical progression have been enrolled in the ACTIV-2 phase 2/3 c...

2021-08-05 22:46 4113
123